GNRH1 and polycystic ovary syndrome: The results of previous reviews showed no differences in CPR28–32, OPR28,29, LBR29, MR30,31, and CCR due to high risk of OHSS31 between PCOS subjects treated with GnRH antagonist protocols and the Long GnRH agonist protocol, which comes along with the results of our review.